ScyFIX

ScyFIX was a medical technology company that developed neuromodulation devices designed to treat degenerative vision loss and various ophthalmic conditions. The company's primary technology, embodied in the ScyFIX 700 device, utilized low-level microcurrent stimulation to revitalize retinal cells and improve blood flow to the eye. Targeted indications included age-related macular degeneration (AMD), retinitis pigmentosa, and Stargardt's disease. While the device received CE Mark approval for commercial sale in Europe and other international markets, the company faced significant regulatory hurdles in the United States. ScyFIX eventually ceased operations after struggling to secure full FDA clearance and sustained funding.